HTG Molecular
HTG Molecular Preliminary Q1 Revenues Fall 56 Percent
For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago.
HTG Molecular Diagnostics FY 2020 Revenues Fall 56 Percent
For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million.Â
HTG Molecular Preliminary 2020 Revenues Drop 56 Percent
The firm reported preliminary revenues of $8.5 million for full-year 2020, which would beat the consensus Wall Street estimate of $8.0 million.
HTG Molecular Completes 1-For-15 Reverse Stock Split
The company stock will now trade on a split-adjusted basis on the Nasdaq after reducing its number of shares from 200 million to 26.7 million.Â
HTG to Expand Disease Reach With New Whole-Transcriptome Profiling Product Mid-2021
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.Â